News | Stroke | March 04, 2016

Imaging, not Time, May Determine Eligibility for Stroke Clot Removal

Researchers use CT perfusion to identify ischemic stroke patients who could benefit from endovascular therapy up to 18 hours after symptom onset

endovascular therapy, stroke clot removal, CT perfusion, brain imaging, International Stroke Conference study

March 4, 2016 — Brain imaging may accurately identify patients likely to benefit from stroke clot removal instead of relying on the time since symptoms began as an indicator of treatment eligibility. The hypothesis was derived from research presented at the American Stroke Association's International Stroke Conference 2016.

An ischemic stroke is caused by lack of blood reaching part of the brain. Endovascular treatment — which mechanically removes the blood clot blocking the path to the brain — benefits patients when performed within six hours of symptom onset. Drug treatment to bust the clot is beneficial up to 4.5 hours.

Here, researchers show that brain imaging can select patients who could benefit from clot removal up to 18 hours after stroke symptoms begin.

Researchers evaluated data on 102 patients who had endovascular therapy up to 18 hours after the start of their stroke and had a computed tomography perfusion (CTP) imaging scan before treatment that showed where a large area of brain tissue may be safely salvaged.

Good recovery — defined as little to no disability — was achieved in 71.4 percent of the patients treated within six hours and 61.7 percent of patients treated beyond six hours of stroke onset. There was no significant association between time to treatment and good outcomes when CT perfusion imaging shows a salvageable brain tissue.

"Using this image-based selection, we would be able to look at any patient who comes through the door to identify the ones likely to benefit from these therapies, regardless of what the clock shows," said Jenny Tsai, M.D., C.M., study author and neuroimaging and vascular neurology fellow at the Stanford Stroke Center. The facility is part of the University of Stanford's School of Medicine in Stanford, Calif.

"This is important because we want to offer the best treatments to every patient who suffers stroke and who may benefit from them. One of the best ways to do this is to have an objective imaging tool to evaluate every single patient," she said.

Researchers analyzed patient data from the clinical study CT Perfusion to predict Response to recanalization in Ischemic Stroke Project (CRISP). The two-year study focused on adults 18 and older and finished in 2014. It was funded by the NIH and conducted at six U.S. medical sites with the goal of developing a practical tool to identify acute stroke patients likely to benefit from endovascular therapy.

"We now have a very effective treatment for the large and disabling acute strokes," Tsai said. "And we know that there are patients likely to benefit from interventional treatments who are not being captured using basic imaging and time criteria alone. We need to do better."

Co-authors are Michael Mlynash, M.D., M.S.; Soren Christensen, Ph.D.; Stephanie Kemp; Nishant Mishra, M.D., Ph.D.; Christian Federau, M.D.; Dipl. Phys. ETH; Sun Kim, M.D.; Michael Frankel, M.D.; Seena Dehkharghani, M.D.; Thomas Devlin, M.D.; Dileep Yavagal, M.D.; Naveed Akhtar, M.D.; Tudor Jovin, M.D.; Raul Nogueira, M.D.; Roland Bammer, Ph.D.; Matus Straka, Ph.D.; Gregory Zaharchuk, M.D., Ph.D; Gregory Albers, M.D.; Michael Marks, M.D.; and Maarten Lansberg, M.D., Ph.D. Author disclosures are on the abstract.

The study was funded by the National Institutes of Health.

For more information: www.strokeconference.org


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now